Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-pubmed-20260411-075356-20920528_20260416-034507",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: Autophagy Paradox Hypotheses\n\n## 1. Translational Potential Ranking\n\nBased on the current Alzheimer's clinical landscape—dominated by anti-amyloid monoclonal antibodies (lecanemab, donanemab), limited neuroprotective options beyond anti-inflammatory approaches, and growing recognition of metabolic dysfunction in AD—here is my assessment:\n\n---\n\n### **Highest Translational Priority: Hypothesis 1 (Autophagosome Overload → LMP) combined with calpain pathway**\n\n**Why this takes priority:**\nThe 2017 source paper explicitly implicates **calpain activation** as the proximal effector. This is the strongest mechanistic anchor available. Critically, calpain inhibitors have already completed Phase 1 safety studies (MNI-797 and others) in stroke and traumatic brain injury, representing a near-term repurposing opportunity. There is a well-characterized patient population: individuals with vascular contributions to cognitive impairment and dementia (VCID), where episodic cerebral hypoperfusion followed by reperfusion is a documented event. This represents a direct analogue to the glucose deprivation/reintroduction paradigm.\n\n**Clinical evidence gap:** No human data showing that calpain inhibition modifies neurodegenerative progression. The stroke TBI literature addresses acute injury, not chronic neurodegeneration. CSF biomarker correlates (cathepsin B activity, Galectin-3) remain in research development with no validated clinical assay.\n\n**Safety considerations:** Pan-calpain inhibition risks disruption of synaptic plasticity, long-term potentiation, and dendritic remodeling—calpains have roles beyond cell death. Selective calpain-1 vs. calpain-2 targeting needs further refinement.\n\n**Patient population fit:** Highly specific. Patients with documented cerebrovascular disease,屡次卒中/TIA history, or cardiac surgery with documented cerebral hypoperfusion episodes. This is a meaningful subpopulation but not the broad AD population.\n\n---\n\n### **Second Priority: Hypothesis 2 (mTORC1/AMPK axis—bioenergetic failure)**\n\n**Why this ranks second:**\nDirectly maps to an enormous literature. The AMPK activator metformin is in multiple AD prevention trials (TAME trial, MILAGE). Ketogenic diets and MCT supplementation are in Phase 2. However, this hypothesis is less specific to the \"autophagy paradox\" finding—it explains metabolic dysfunction broadly rather than the counterintuitive protective effect of autophagy blockade.\n\n**Current clinical evidence:** Metformin use associated with reduced AD risk in some retrospective cohorts; mechanistic causality not established. Ketogenic interventions show signal in MCI but limited data in established AD.\n\n**Safety considerations:** AMPK activation has complex systemic effects; mTORC1 inhibition affects immune function and may impair lysosomal turnover in other contexts.\n\n**Patient population fit:** Broad metabolic phenotype fits many AD patients, but loses specificity for the finding's mechanistic novelty.\n\n---\n\n### **Third Priority: Novel mechanism (calcium-calpain-NLRP3 axis)**\n\nI would argue this deserves investigation but is early-stage. Calpain-mediated lysosomal permeabilization could",
  "tokens_used": "796"
}